EDISON EQUITY RESEARCH - ANGLE
September 11 2015 - 12:58AM
InvestorsHub NewsWire
EDISON EQUITY RESEARCH: ANGLE - CELLS FOR PRECISION
MEDICINE
Angle has transformed into a pure-play diagnostics business.
Parsortix, its proprietary cell separation system, can be used to
capture and harvest very rare cells from blood for analysis,
including circulating tumour cells. Information gained from these
cells is essential to a precision medicine approach, a key
initiative aiming to improve clinical outcomes. In the near term,
Parsortix is being evaluated for use in the pre-surgery triaging of
ovarian masses, which could see clinical sales as early as FY H217.
Parsortix is launched for the research market and, and for the
clinical market has a CE mark in Europe. An FDA application is in
progress for the US. We value Angle at $143m or $24/ADS.
Cerulean is a US-based oncology company with a proprietary platform
utilizing nanoparticle-drug conjugates (NDCs). Lead product CRLX101
combined with Avastin is in Phase II clinical trials in third- and
fourth-line RCC and second- and third-line ovarian cancer. CRLX101
in combination with chemotherapy is also in Phase Ib/IIa in
neoadjuvant rectal cancer.
To view our full report, please click here
Click here to view all of Edison
Investment Research’s published reports
Angle Plc Surrey (QX) (USOTC:ANPCY)
Historical Stock Chart
From Sep 2024 to Oct 2024
Angle Plc Surrey (QX) (USOTC:ANPCY)
Historical Stock Chart
From Oct 2023 to Oct 2024